Open AccessClinical association of metabolic syndrome, C‐reactive protein and testosterone levels with clinically significant prostate cancer
Author(s) -
GómezGómez Enrique,
CarrascoValiente Julia,
CamposHernández Juan Pablo,
BlancaPedregosa Ana Maria,
JiménezVacas Juan Manuel,
RuizGarcía Jesus,
ValeroRosa Jose,
Luque Raul Miguel,
RequenaTapia María José
Publication year - 2019
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13994
Subject(s) - metabolic syndrome , medicine , prostate cancer , c reactive protein , prostate biopsy , odds ratio , biopsy , testosterone (patch) , prostate , oncology , cancer , gastroenterology , endocrinology , inflammation , obesity
Recently, the influence that metabolic syndrome (MetS), hormonal alterations and inflammation might have on prostate cancer ( PC a) risk has been a subject of controversial debate. Herein, we aimed to investigate the association between MetS‐components, C‐reactive protein ( CRP ) and testosterone levels, and the risk of clinically significant PC a (Sig‐ PC a) at the time of prostate biopsy. For that, men scheduled for transrectal ultrasound guided biopsy of the prostate were studied. Clinical, laboratory parameters and criteria for MetS characterization just before the biopsy were collected. A total of 524 patients were analysed, being 195 (37.2%) subsequently diagnosed with PC a and 240 (45.8%) meet the diagnostic criteria for MetS. Among patients with PC a, MetS‐diagnosis was present in 94 (48.2%). Remarkably, a higher risk of Sig‐ PC a was associated to MetS, greater number of MetS‐components and higher CRP levels (odds‐ratio: 1.83, 1.30 and 2.00, respectively; P < 0.05). Moreover, higher circulating CRP levels were also associated with a more aggressive Gleason score in PC a patients. Altogether, our data reveal a clear association between the presence of MetS, a greater number of MetS‐components or CRP levels >2.5 mg/L with an increased Sig‐ PC a diagnosis and/or with aggressive features, suggesting that MetS and/or CRP levels might influence PC a pathophysiology.